Preparation method and application of activating antibody-modified photonic crystal hydrogel hybrid drug-loaded microspheres

Abstract

The invention discloses a preparation method and application of an activating antibody-modified photonic crystal hydrogel hybrid drug-carrying microsphere. The preparation method includes the following steps: step 1, preparing photonic crystal microspheres with a pore structure; step 2, Drug loading: The photonic crystal microspheres are immersed in a drug-containing hydrogel solution, and the hydrogel is cured and the drug is locked by ultraviolet light irradiation to obtain a photonic crystal hydrogel hybrid drug-loaded microsphere; the drug is a cytokine; Step 3. Antibody modification: The photonic crystal hydrogel hybrid drug-loaded microspheres are soaked in a buffer containing monoclonal antibody, and the monoclonal antibody is coupled to the photonic crystal hydrogel hybrid drug-loaded by chemical grafting reaction On the surface of the microspheres, activated antibody-modified photonic crystal hydrogel hybrid drug-loaded microspheres were obtained. The microspheres prepared by the invention can carry cytokines such as activating antibodies and cell growth-promoting cells, can promote the activation of T cells in vitro, and realize the in vitro expansion of T cells.

Description

technical field [0001] The invention belongs to the field of biological materials, and relates to a drug-loaded microsphere, in particular to a preparation method and application of an activated antibody-modified photonic crystal hydrogel hybrid drug-loaded microsphere. Background technique [0002] Tumor immunotherapy is an emerging tumor treatment plan. It is a powerful tumor killing treatment method by activating the autoimmune system of tumor patients to enhance their own anti-tumor ability. It has the advantages of less side effects and wide indications. However, the immunosuppressive microenvironment inside the tumor always impairs the tumor-killing process of T cells. Clinically, this problem is mainly solved by the infusion of immune effector cells activated in vitro into the patient, which is also called adoptive cell therapy (ACT). The number of immune effector cells required for clinical treatment is extremely large, and a very effective in vitro expansion system...

AI Technical Summary

Problems solved by technology

However, the current systems for expanding immune effector cells in vitro are often nano-scaffold materials, which are prone to toxicity to immune effector cells, and their expansion efficiency needs to be improved.

Images